Case conference

- Case ID: 1184xxxx
 - R2 鄭凱文
- Supervisor VS 林立偉
 - 2014/11/24

Patient Profile

- 36Y/o ♂
- 2014/xx/xx 23:22
- E4V5M6
- T/P/R=36.6/107/18; BP = 137/91mmHg
- SpO2 = 98%
- 檢傷主訴:病人主訴為腹痛、吐、冒汗 (痛苦指數 08)
- Triage = Π

Present Illness

- · C.C: abd. Pain tonight
- · Vomitus twice, non-bilious
- · epigastric, intermittent cramping; no radiation
- alcohol (-)
- diarrhea (-)
- cold sweating (+)

Past History

- NKDA
- · Abd. OP: nil
- DM under OHA (規律服藥)

Physical Examination

- Cons. Clear
- · not well-looking
- · neck supple
- clear BS; deep respiration (Kussmaul?)
- ahd ·
 - soft, slight distended
 - No Murphy sign
- · No inguinal/scrotal swelling
- warm ext.
- N.E.: grossly intact




Impression

- Abd. Pain, susp. DKA
- · r/o pancreatitis
- r/o ileus
- · r/o atypical ACS

Initial order (day 1, 23:30)

- EKG
- F/S (352) → RI 10units sc st
- CBC, D/C, plt
- · Crea., AST, CI, T-bil., lipase, troponin-I
- B/C* I
- N/S 500mL st, then run 100mL/hr
- Ketone
- KUB
- NOVA (VBG, Na, K)





HCO₃- 20.5 mgmol L
TCO₂ 21.4 mmol L
BEECF -3.4 mmol L
BEBb -1.0 mmol L
SBC 23.5 mmol L
A 116.5 mmHg
A-aDO₂ 51.0 mmHg
a/A 0.6
RI 0.8
PO₂FIO₂ 313.5 mmHg
SO₂% 94.2
Hb 17.3 g/d L
nCa** 4.21 mg/d L

mmHg mmHg % mmol/L		Lab	data		
mmol/L	100	CBC, Plt, D/C		生化 人	× -
mg/dL		WBC	14.8x1000/µL	12	
mg/dL	211	RBC	4.71x10^6/µL	AST	0.00
mg/dL	1303	Hb	13.9gm/dL	T-Bil.	0.99
		Hct	39.4%	Crea.	2.42
ts - Calculated	1 12	MCV	83.7fL	.eGFR	s muld
is - Calculated				CI	97m
mmol/L	18	MCH	29.5pg	Lipase	43
mmol/L		MCHC	35.3%	Troponin-I	į.
mmol/L		RDW	13.3%	поролиг	
mmol·L	- 3	Plt	314x1000/µL		
mmol/L		Differential of	count		
mmHg		Seg.	60.0%		
mmHg	150	Lymph.	6.0%		
		Monocyte	5.0%		
	77 100	Eccionophil	0.09/		

0.0%

EKG

Day 2, 00:38

- NG decompression
- · Promeran ivd st
- B/C* I (2nd)
- Ceftriaxone 2g ivd st
- Metronidazole 500mg ivd st
- Sign CT permit
- on 2nd line

Day 2, 01:29 bedside echo

Basophil Aty. Lymph Band

Metamyelo Myelocyte

- No ascites
- · No hydronephrosis
- no gall stone
- small bowel wall thickening (+)
- no CBD dilatation

Day 2

- WBC 14.8k (band 25%)
- 02:46
 - recheck BP/HR (36.4/96/16; 129/84mmHg)
 - abd. CT w/o contrast
 - TG, LDH

生化。	
Ketone	0.6mmol/L
LDH	645U/L
TG	2805mg/dL

Table 82-5 CT Severity Index for Acute Pancreatitis Grade of Acute Pancreatitis Normal pancreas Pancreatic enlargement Inflammation involving pancreas and peripancreatic fat Single fluid collection or phlegmon Two or more fluid collections or phlegmons Degroe of Pancreatic Necrosis No necrosis No necrosis Necrosis of one third of pancreas Vecrosis of one half of pancreas Interpretation (minimum score = 0 and maximum score = 10) Severity Index Mortality (%) Complications (%) 0 - 1 2 - 3 3 4 - 6 6 7 - 10 17 92


EC order, day 2, 10:07

- O2 mask 6L/min
- on monitor
- IVF D5S 120mL/hr
- Foy 100mg in N/S 500mL run 20mL/hr
- NPO + NG decompression
- Meropenem 500mg ivd st, 250mg ivd q6h
- 聯絡 ICU
- · on critical
- · admission to AICU

Abd. CT

Day 2

- 已和病人 & family 解釋 severity↑ · mortality & complication rate ↑
- 03:36
 - 排GI床
 - Check F/S & BP/HR q4h
 - 待轉 EC
- N/S 500mL st
- 05:45
 - N/S 500mL st
- 08:34
 - 轉 EC30




Then...

- Day2:
 - O2 mask 6~10L/min
 - D5S 500mL + RI 10units run 120mL/hr
- Day3:
 - Rasitol 2amp iv q6h (U/O = 45)
 - \rightarrow DC (I/O = -1172)
 - 500mL iv st *7 次 ightarrow U/O > 50mL/hr
- Day4: O2 N/C 4L/min

pH	6.85
pCO ₂	52.6
pO ₂	64
HCO ₃ -	9.2
Na	148
K	6.2

- Day5:
 - Sudden loss of consciousness
 - → Intubation
 - Rasitol 2amp iv q6h
 - on CVVH
- Day8: D5W 250mL via NG q8h + on TPN
- Day9: 轉 MI · Day10: extubation
- Day11: 轉一般病房 • Day27: MBD

Lipase



Discussion

1031105-0923

日期

Crea.

128.438.498.498.28

1031108-0628

1031114-1022

1031120-1312

10.41

13

12

10

1031101-1652

1031030-0706

1031102-0657

1031103-0643

檢驗值

Tenner S, Baillie J, Dewitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-15.


Diagnosis

- 三項符合兩項
 - abdominal pain consistent with the disease
 - serum amylase / lipase > 3X the upper limit of normal
 - characteristic findings from abdominal imaging
- contrast CT / MRI of the pancreas should be reserved for patients in whom
 - the diagnosis is unclear
 - fail to improve clinically within the first 48 72 h after hospital admission

Etiology

- Transabdominal ultrasound should be performed in all patients
- · In the absence of gallstones / significant history of alcohol use,
 - a serum triglyceride should be obtained and considered the etiology if > 1,000 mg/dl
- > 40y/o, a pancreatic tumor should be considered as a possible cause
- Endoscopic investigation in patients with acute idiopathic pancreatitis should be limited

Initial assessment & risk stratification



Patients with organ failure / SIRS → ICU

- · the preferred isotonic crystalloid replacement fluid
 - → Lactated Ringer's solution
- Fluid requirements should be reassessed at frequent intervals
 - within 6 h of admission
 - for the next 24 48 h
- The goal of aggressive hydration
 - → to decrease the blood urea nitrogen

Table 4. Clinical findings associated with a severe course for initial risk assessment* Patient characteristics Age >55 years (\$3.57) Obesity (\$M1 > 30 kg/m²) (68) Altered mental status (69) Comorbid disease (\$53) Altered mental status (69) Comorbid disease (\$53) The systemic inflammadory response syndrome (\$IR\$3) (\$5.3,54,70,71) Presence of >2 of the following criteria: — public >90 beals/min — espirations >20/min or PaCO, >32 mm Hg — temperature >38°C or <36°C —WBG count >12,000 or <4,000 cels/min³ or >10% immature neutrophils (bands) Laboratory findings BUN >20 mgldi (\$3) Roing BUN (\$3) HCT >44% (\$62) Baing HCT (\$62) Baing HCT (\$62) Baing HCT (\$62) Baing HCT (\$62) Multiple or adentifye extrapancreatic collections (\$67) BMI, body mass index; BUN, blood urea mitrogen; HCT, hematocnt; WBC, white blood cell. **The presence of organ failure and/or parcreatic necrosis defines severe acute*

Initial management

- · Aggressive hydration
 - 250-500 ml/hr of isotonic crystalloid solution
 - unless cardiovascular / renal comorbidites exist
 - Early aggressive intravenous hydration is most beneficial the first 12 – 24 h
- · In a patient with severe volume depletion
 - manifest as hypotension and tachycardia,
 - \rightarrow more rapid repletion (bolus)

ERCP in acute pancreatitis

- acute pancreatitis with concurrent acute cholangitis
 - → should undergo ERCP within 24h of admission
- ERCP is not needed in most patients with gallstone pancreatitis
 - who lack laboratory or clinical evidence of ongoing biliary obstruction
- $\bullet\,$ In the absence of cholangitis and/or jaundice

to screen for highly suspected choledocholithiasis

- MRCP or endoscopic ultrasound (EUS) first
- rather than diagnostic ERCP
- Pancreatic duct stents / postprocedure rectal NSAID suppositories should be utilized to prevent severe post-ERCP pancreatitis in high-risk patients

The role of antibiotics in acute pancreatitis

- Antibiotics should be given for an extrapancreatic infection
 - Cholangitis
 - catheter-acquired infections
 - bacteremia, urinary tract infections, pneumonia
- Routine use of prophylactic antibiotics in patients with severe acute pancreatitis is not recommended
- The use of antibiotics in patients with sterile necrosis to prevent the development of infected necrosis is not recommended
- Infected necrosis should be considered in patients with pancreatic or extrapancreatic necrosis who deteriorate or fail to improve after 7 – 10 days of hospitalization. In these patients, either should be given
 - (i) initial CT-guided FNA for Gram stain and culture to guide use of appropriate antibiotics
 - (ii) empiric use of antibiotics without CT FNA

- In patients with infected necrosis, antibiotics known to penetrate pancreatic necrosis
 - carbapenems, quinolones, and metronidazole
 - may be useful in delaying or sometimes totally avoiding intervention
- Routine administration of antifungal agents is not recommended

Nutrition in acute pancreatitis

- In mild AP, oral feedings can be started immediately if there is no nausea and vomiting, and abdominal pain has resolved
- In mild AP, initiation of feeding with a low-fat solid diet appears as safe as a clear liquid diet
- In severe AP, enteral nutrition is recommended to prevent infectious complications.
 - Parenteral nutrition should be avoided unless the enteral route is not available, not tolerated, or not meeting caloric requirements
- Nasogastric delivery and nasojejunal delivery of enteral feeding appear comparable in efficacy and safety